Jenner & Block represented Clementia Pharmaceuticals Inc., a Montreal, Canada-based clinical stage biopharmaceutical company, in its initial public offering of common shares and Nasdaq listing. The total offering size was 9,191,000 common shares for gross proceeds of approximately $137.9 million. The shares began trading on The NASDAQ Global Select Market on August 2, 2017 under the ticker symbol "CMTA."
The exercise of the underwriters’ over-allotment option closed on August 18, 2017. Clementia is focused on developing treatments for rare bone diseases and intends to use the net proceeds of the offering primarily to fund the clinical trials of its product candidates.
Morgan Stanley & Co. LLC and Leerink Partners LLC acted as book-running managers for the offering. Wedbush Securities Inc. and BTIG, LLC acted as co-managers for the offering.
Led by Corporate Partners Kevin T. Collins and Martin Glass, the team included Associate Breanne K. Long and former associate Inna Gelgat. Partners S. Tony Ling (Executive Compensation), Geoffrey M. Davis (Tax) and Anouck Giovanola (Compliance) provided valuable assistance.